FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204646977> ?p ?o ?g. }

• W3204646977 abstract "In this study, we aimed to evaluate axillary lymph node dissection (ALND) rates and prognosis in neoadjuvant chemotherapy (NCT) compare with neoadjuvant endocrine therapy (NET) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), lymph node (LN)-positive, premenopausal breast cancer patients (NCT01622361). The multicenter, phase 3, randomized clinical trial enrolled 187 women from July 5, 2012, to May 30, 2017. The patients were randomly assigned (1:1) to either 24 weeks of NCT including adriamycin plus cyclophosphamide followed by intravenous docetaxel, or NET involving goserelin acetate and daily tamoxifen. ALND was performed based on the surgeon's decision. The primary endpoint was ALND rate and surgical outcome after preoperative treatment. The secondary endpoint was long-term survival. Among the 187 randomized patients, pre- and post- neoadjuvant systemic therapy (NST) assessments were available for 170 patients. After NST, 49.4% of NCT patients and 55.4% of NET patients underwent mastectomy after treatment completion. The rate of ALND was significantly lower in the NCT group than in the NET group (55.2% vs. 69.9%, P=.046). Following surgery, the NET group showed a significantly higher mean number of removed LNs (14.96 vs. 11.74, P=.003) and positive LNs (4.84 vs. 2.92, P=.000) than the NCT group. The axillary pathologic complete response (pCR) rate was significantly higher in the NCT group (13.8% vs. 4.8%, P=.045) than in the NET group. During a median follow-up of 67.3 months, 19 patients in the NCT group and 12 patients in the NET group reported recurrence. The 5-year ARFS (97.5%vs. 100%, P=.077), DFS (77.2% vs. 84.8%, P=.166), and OS (97.5% vs. 94.7%, P=.304) rates did not differ significantly between the groups. In conclusion, although survival did not differ significantly, more NCT patients might able to avoid ALND, with fewer LNs removed with lower LN positivity.https://clinicaltrials.gov/ct2/show/NCT01622361, identifier NCT01622361." @default.
• W3204646977 created "2021-10-11" @default.
• W3204646977 creator A5004494566 @default.
• W3204646977 creator A5005022842 @default.
• W3204646977 creator A5010518834 @default.
• W3204646977 creator A5010781894 @default.
• W3204646977 creator A5010796867 @default.
• W3204646977 creator A5013544822 @default.
• W3204646977 creator A5037295746 @default.
• W3204646977 creator A5052099934 @default.
• W3204646977 creator A5057636290 @default.
• W3204646977 creator A5082400192 @default.
• W3204646977 creator A5085180691 @default.
• W3204646977 date "2021-09-30" @default.
• W3204646977 modified "2023-10-18" @default.
• W3204646977 title "Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer" @default.
• W3204646977 cites W1878299132 @default.
• W3204646977 cites W1954609011 @default.
• W3204646977 cites W1955397179 @default.
• W3204646977 cites W1966064734 @default.
• W3204646977 cites W1972645288 @default.
• W3204646977 cites W1974685860 @default.
• W3204646977 cites W1984107586 @default.
• W3204646977 cites W1986613379 @default.
• W3204646977 cites W1989616257 @default.
• W3204646977 cites W1993544627 @default.
• W3204646977 cites W2009157719 @default.
• W3204646977 cites W2017587209 @default.
• W3204646977 cites W2026828444 @default.
• W3204646977 cites W2032207130 @default.
• W3204646977 cites W2033363991 @default.
• W3204646977 cites W2053074390 @default.
• W3204646977 cites W2064769417 @default.
• W3204646977 cites W2070281077 @default.
• W3204646977 cites W2081395163 @default.
• W3204646977 cites W2083335978 @default.
• W3204646977 cites W2087393207 @default.
• W3204646977 cites W2095599161 @default.
• W3204646977 cites W2096785769 @default.
• W3204646977 cites W2103218083 @default.
• W3204646977 cites W2114264989 @default.
• W3204646977 cites W2117775530 @default.
• W3204646977 cites W2118605519 @default.
• W3204646977 cites W2128995479 @default.
• W3204646977 cites W2142059226 @default.
• W3204646977 cites W2147415463 @default.
• W3204646977 cites W2161911084 @default.
• W3204646977 cites W2162760540 @default.
• W3204646977 cites W2166730440 @default.
• W3204646977 cites W2172114428 @default.
• W3204646977 cites W2196732725 @default.
• W3204646977 cites W2326824641 @default.
• W3204646977 cites W2327133772 @default.
• W3204646977 cites W2346232596 @default.
• W3204646977 cites W2516525501 @default.
• W3204646977 cites W2599030125 @default.
• W3204646977 cites W2740555921 @default.
• W3204646977 cites W2741673034 @default.
• W3204646977 cites W2803564892 @default.
• W3204646977 cites W2859812293 @default.
• W3204646977 cites W3013290426 @default.
• W3204646977 cites W3030529007 @default.
• W3204646977 cites W3048442532 @default.
• W3204646977 cites W3122861570 @default.
• W3204646977 cites W3179495039 @default.
• W3204646977 doi "https://doi.org/10.3389/fonc.2021.741120" @default.
• W3204646977 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8515848" @default.
• W3204646977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34660302" @default.
• W3204646977 hasPublicationYear "2021" @default.
• W3204646977 type Work @default.
• W3204646977 sameAs 3204646977 @default.
• W3204646977 citedByCount "1" @default.
• W3204646977 countsByYear W32046469772023 @default.
• W3204646977 crossrefType "journal-article" @default.
• W3204646977 hasAuthorship W3204646977A5004494566 @default.
• W3204646977 hasAuthorship W3204646977A5005022842 @default.
• W3204646977 hasAuthorship W3204646977A5010518834 @default.
• W3204646977 hasAuthorship W3204646977A5010781894 @default.
• W3204646977 hasAuthorship W3204646977A5010796867 @default.
• W3204646977 hasAuthorship W3204646977A5013544822 @default.
• W3204646977 hasAuthorship W3204646977A5037295746 @default.
• W3204646977 hasAuthorship W3204646977A5052099934 @default.
• W3204646977 hasAuthorship W3204646977A5057636290 @default.
• W3204646977 hasAuthorship W3204646977A5082400192 @default.
• W3204646977 hasAuthorship W3204646977A5085180691 @default.
• W3204646977 hasBestOaLocation W32046469771 @default.
• W3204646977 hasConcept C121608353 @default.
• W3204646977 hasConcept C126322002 @default.
• W3204646977 hasConcept C141071460 @default.
• W3204646977 hasConcept C143998085 @default.
• W3204646977 hasConcept C168563851 @default.
• W3204646977 hasConcept C203092338 @default.
• W3204646977 hasConcept C2776694085 @default.
• W3204646977 hasConcept C2776755627 @default.
• W3204646977 hasConcept C2777176818 @default.
• W3204646977 hasConcept C2778292576 @default.
• W3204646977 hasConcept C2780212769 @default.
• W3204646977 hasConcept C2780849966 @default.
• W3204646977 hasConcept C2781190966 @default.
• W3204646977 hasConcept C2908949552 @default.

• next